Astrocyte Pharmaceuticals has begun its first-in-human Phase 1 clinical study with the dosing of a first subject with AST-004, a promising investigational therapeutic being advanced as a potential acute treatment for stroke and traumatic brain injury victims and as a chronic treatment for neurodegenerative diseases like Alzheimer’s.
“AST-004 demonstrated significant safety in the required regulatory animal studies, and we look forward to taking this next step of understanding its safety and pharmacokinetics in humans,” said Lisa Manna, Vice President of Clinical Development Operations at Astrocyte.